InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Head and Neck Cancer Market- by Products (Cytotoxic Agents, Antimetabolites, Abitrexate/Mexate/Folex (methotrexate), Hydrea (hydroxyurea), Antitubulins, Taxotere (docetaxel), Others (Platinum Agents, Fluoropyrimidines), Platinol (cisplatin), 5-fluorouracil (5-FU), EGFR Inhibitors (mAbs), Erbitux (cetuximab), Vectibix (panitumumab), Theracim/Theraloc (nimotuzumab), EGFR Inhibitors (TKIs), Tarceva (erlotinib), Iressa (gefitinib), Tykerb/Tyverb (lapatinib), PD1 Inhibitors, Keytruda (pembrolizumab), Opdivo (nivolumab), Pipeline Drugs (Late-stage), EGFR Inhibitors (mAbs), Vectibix (panitumumab), PDL1 Inhibitors, Imfinzi (durvalumab), Bavencio (avelumab), CTLA4 Inhibitors, Yervoy (ipilimumab) and Tremelimumab), Trends, Industry Competition Analysis, Revenue and Forecast To 2034.”
According to the Global Head and Neck Cancer Market Size is estimated to grow at a CAGR of 8.5% during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1217
Head and neck cancer is caused mainly by squamous cells, which line the mucosal surfaces of the head and neck, including the interior of the mouth, nose, and throat. Head and neck cancers can affect the salivary glands, pharynx, larynx, paranasal sinuses, nasal cavity, and oral cavity. There are approximately 630,000 new cases of head and neck cancer (HNC) each year, making it the sixth most common cancer globally.
The main factor driving the head and neck cancer market is the rise in head and neck malignancies. The aging population, substantial financing for oncology research, unmet medical needs, growing market rivalry, improved regulatory framework, the aging population, and rising government support are a few additional factors driving the growth of the global head and neck cancer market. The head and neck cancer sector nevertheless raises worries despite these reasons. The high cost of therapy may hamper market expansion, the drawbacks of present treatments, the lack of healthcare coverage, and the inadequate healthcare systems in low- and middle-income nations.
North America is anticipated to be the major contributor to the Head and Neck Cancer market over the forecast years due to the rising incidence of head and neck cancer, rising use of cutting-edge medical technologies, large market player presence, high healthcare costs, and increased knowledge of contemporary cancer treatments. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1217
Major market players operating in the Head and Neck Cancer market include
Advaxis, Inc. (US), Amgen, Inc. (US), AstraZeneca plc (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.) (Japan), Cel-Sci Corporation (US), Five Prime Therapeutics, Inc. (US), GlaxoSmithKline plc (UK), Incyte Corporation (US), IRX Therapeutics, Inc. (US), MacroGenics, Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer, Inc., Roche Holdings AG (Genentech) (Switzerland), Viracta Therapeutics (US) among others.
Recent collaborations and agreements in the market:
- In July 2021, Novartis (Switzerland) partnered with Kura Oncology, Inc., a clinical-stage biopharmaceutical company, to assess the efficacy of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma.
- In June 2021, CEL-SCI Corporation (United States) revealed the results of a 9.5-year pivotal Phase 3 research for its immunotherapy Multikine (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). In a significant head and neck cancer phase 3 study, CEL-Multikine® SCI’s Immunotherapy achieved a 14.1% 5-year survival benefit (62.7% vs 48.6%) in the group undergoing surgery plus radiotherapy.
Get Specific Chapter/Information From The Report:@
https://www.insightaceanalytic.com/customisation/1217
Market Segments
Global Head and Neck Cancer Market, by Products, 2025-2034 (Value US$ Mn)
- Cytotoxic Agents
- Antimetabolites
- Abitrexate/ Mexate/ Folex (methotrexate)
- Hydrea (hydroxyurea)
- Antitubulins
- Taxotere (docetaxel)
- Others (Platinum Agents, Fluoropyrimidines)
- Platinol (cisplatin)
- 5-fluorouracil (5-FU)
- EGFR Inhibitors (mAbs)
- Erbitux (cetuximab)
- Vectibix (panitumumab)
- Theracim/Theraloc (nimotuzumab)
- EGFR Inhibitors (TKIs)
- Tarceva (erlotinib)
- Iressa (gefitinib)
- Tykerb/Tyverb (lapatinib)
- PD1 Inhibitors
- Keytruda (pembrolizumab)
- Opdivo (nivolumab)
- Pipeline Drugs (Late-stage)
- EGFR Inhibitors (mAbs)
- Vectibix (panitumumab)
- PDL1 Inhibitors
- Imfinzi (durvalumab)
- Bavencio (avelumab)
- CTLA4 Inhibitors
- Yervoy (ipilimumab)
- Tremelimumab
Global Head and Neck Cancer Market, by Region, 2025-2034 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Head and Neck Cancer Market, by Country, 2025-2034 (Value US$ Mn)
- S.
- Canada
Europe Head and Neck Cancer Market, by Country, 2025-2034 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Head and Neck Cancer Market, by Country, 2025-2034 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Head and Neck Cancer Market, by Country, 2025-2034 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Head and Neck Cancer Market, by Country, 2025-2034 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Get More information:
https://www.insightaceanalytic.com/report/global-head-and-neck-cancer-market/1217
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
